Key Insights on Catalent (CTLT) that You Might Have Overlooked

Shares of Health Care sector company Catalent moved -0.3% today, and are now trading at a price of $47.07. The large-cap stock's daily volume was 91,506 compared to its average volume of 2,624,947. The S&P 500 index returned a -0.0% performance.

Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. The company is based in Somerset and has 17,800 full time employees. Its market capitalization is $8,485,403,136.

14 analysts are following Catalent and have set target prices ranging from $44.0 to $58.0 per share. On average, they have given the company a rating of hold. At today's prices, CTLT is trading -8.23% away from its average analyst target price of $51.29 per share.

Over the last year, CTLT shares have gone down by -46.0%, which represents a difference of -62.0% when compared to the S&P 500. The stock's 52 week high is $89.69 per share and its 52 week low is $31.45.

Date Reported Cash Flow from Operations ($ k) Capital expenditures ($ k) Free Cash Flow ($ k) YoY Growth (%)
2022-08-29 439,000 -660,000 1,099,000 -1.79
2021-08-30 433,000 -686,000 1,119,000 23.51
2020-08-31 440,000 -466,000 906,000 94.84
2019-08-27 248,000 -217,000 465,000 -15.33
2018-08-28 374,500 -174,700 549,200 25.22
2017-08-28 299,500 -139,100 438,600
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.